Palvella Therapeutics (PVLA) Income from Continuing Operations: 2013-2024
Historic Income from Continuing Operations for Palvella Therapeutics (PVLA) over the last 11 years, with Dec 2024 value amounting to -$4.0 million.
- Palvella Therapeutics' Income from Continuing Operations fell 128.55% to -$4.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$17.4 million, marking a year-over-year decrease of 74.03%. This contributed to the annual value of -$17.4 million for FY2024, which is 193.27% down from last year.
- Per Palvella Therapeutics' latest filing, its Income from Continuing Operations stood at -$4.0 million for Q4 2024, which was up 41.68% from -$6.8 million recorded in Q3 2024.
- In the past 5 years, Palvella Therapeutics' Income from Continuing Operations ranged from a high of $13.8 million in Q4 2023 and a low of -$19.0 million during Q3 2021.
- Moreover, its 3-year median value for Income from Continuing Operations was -$7.1 million (2022), whereas its average is -$5.9 million.
- Its Income from Continuing Operations has fluctuated over the past 5 years, first slumped by 1,508.69% in 2020, then spiked by 223.93% in 2023.
- Quarterly analysis of 5 years shows Palvella Therapeutics' Income from Continuing Operations stood at -$12.4 million in 2020, then rose by 11.27% to -$11.0 million in 2021, then fell by 1.48% to -$11.2 million in 2022, then surged by 223.93% to $13.8 million in 2023, then plummeted by 128.55% to -$4.0 million in 2024.
- Its Income from Continuing Operations was -$4.0 million in Q4 2024, compared to -$6.8 million in Q3 2024 and -$4.2 million in Q2 2024.